Primitive neuroectodermal tumor
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Primitive neuroectodermal tumor
- Therapeutic area
- Oncology
- primitive neuroectodermal tumor
- PNET
- neuroectodermal neoplasm
- neuroectodermal tumor
- neuroectodermal tumour
- primitive neuroectodermal neoplasm
- primitive neuroectodermal tumor
- primitive neuroectodermal tumor (PNET)
- primitive neuroectodermal tumour (PNET)
- Severity
- Severe
- Neurology
- Oncology
- MONDO ID
- MONDO:0005462
- Parent condition
- MONDO:0005564
Related records
Broader conditions (11)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Embryonal neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Nervous system disorder
- Nervous system neoplasm
- Neuroepithelial neoplasm
Narrower conditions (42)
- Adrenal gland ganglioneuroblastoma
- Adrenal gland neuroblastoma
- Adult central nervous system primitive neuroectodermal neoplasm
- Adult embryonal tumor with multilayered rosettes, c19mc-altered
- Askin tumor
- Central nervous system primitive neuroectodermal neoplasm
- Central nervous system tumor with bcor internal tandem duplication
- Cerebral neuroblastoma
- Cervical neuroblastoma
- Childhood central nervous system primitive neuroectodermal neoplasm
- Childhood supratentorial embryonal tumor with multilayered rosettes, C19MC-altered
- Cns neuroblastoma with FOXR2 activation
- Cutaneous ganglioneuroma
- Differentiating neuroblastoma
- Dopaminergic neuroblastoma
- Ependymoblastoma
- Extracranial neuroblastoma
- Ganglioneuroblastoma
- Ganglioneuroma
- Intermixed schwannian stroma-rich ganglioneuroblastoma
Trials (65)
- 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma
- 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
- A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
- A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas
- A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
- A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
- A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
- Adjuvant Trial in Pancreatic Neuroendocrine Tumors
- Agnostic Therapy in Rare Solid Tumors
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
- Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
- Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
- BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
- Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
- Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
- Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
Drugs in development (11)
- Antineoplaston A10 Phase 2
- Carboplatin Phase 3
- Cisplatin Phase 3
- Cyclophosphamide Phase 3
- Etoposide Phase 3
- Filgrastim Phase 3
- Leucovorin calcium Phase 3
- Methotrexate Phase 3
- Thiotepa Phase 3
- Tipifarnib Phase 2
- Vincristine sulfate Phase 3
Other linked drugs (1)
- Vorasidenib